1. Home
  2. BEAM vs SPNS Comparison

BEAM vs SPNS Comparison

Compare BEAM & SPNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$26.09

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

SPNS

Sapiens International Corporation N.V. (Cayman Islands)

HOLD

Current Price

$43.44

Market Cap

2.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
SPNS
Founded
2017
1982
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.4B
IPO Year
2020
1992

Fundamental Metrics

Financial Performance
Metric
BEAM
SPNS
Price
$26.09
$43.44
Analyst Decision
Strong Buy
Hold
Analyst Count
12
3
Target Price
$48.09
$31.33
AVG Volume (30 Days)
1.9M
556.5K
Earning Date
11-04-2025
11-13-2025
Dividend Yield
N/A
1.38%
EPS Growth
N/A
N/A
EPS
N/A
1.15
Revenue
$55,701,000.00
$564,331,000.00
Revenue This Year
N/A
$8.80
Revenue Next Year
$26.52
$6.98
P/E Ratio
N/A
$37.78
Revenue Growth
N/A
4.71
52 Week Low
$13.53
$23.69
52 Week High
$35.25
$43.52

Technical Indicators

Market Signals
Indicator
BEAM
SPNS
Relative Strength Index (RSI) 52.89 71.89
Support Level $25.86 $43.27
Resistance Level $28.10 $43.52
Average True Range (ATR) 1.63 0.06
MACD 0.06 0.01
Stochastic Oscillator 47.65 82.91

Price Performance

Historical Comparison
BEAM
SPNS

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About SPNS Sapiens International Corporation N.V. (Cayman Islands)

Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.

Share on Social Networks: